CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 409 enrolled
Drug / intervention
Tramadol +1 moredrug
Likely dose
Tramadol 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03290378
NCT03290378Phase 3Completed

A Phase 3, Multicenter, Randomized, Double Blind, Three-Arm Study to Evaluate the Efficacy and Safety of Tramadol Infusion (AVE-901) Versus Placebo in the Management of Postoperative Pain Following Bunionectomy

Avenue Therapeutics, Inc.·interventional·Posted Sep 21, 2017·Updated Mar 19, 2020

In Brief

A Phase 3 clinical trial evaluating Tramadol and Placebo for Pain Management. Completed, enrolled 409 participants across 5 sites.

Detailed Summary

The study evaluates the effectiveness and safety of IV tramadol compared to placebo managing postoperative pain following a bunionectomy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain Management
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 21, 2017
Enrollment StartSep 19, 2017
Primary CompletionApr 11, 2018
Study CompletionApr 23, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.8 years ago

Interventions

Tramadoldrug

IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44

Placeboother

IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44